Stockholm, September 13, 2024. An extraordinary general meeting of Asarina Pharma AB (publ) ("Asarina" or the "Company") decided on August 21, 2024 that the Company shall enter into voluntary liquidation. In light of this, the Company's board has today decided to apply for the delisting of the Company's shares from the Nasdaq First North Growth Market in Stockholm.
On 22 July 2024, Asarina published the board's proposal for an extraordinary general meeting to decide on voluntary liquidation of the Company. The proposal was submitted against the background that in mid-July 2024 the Company's partner process had not resulted in tenders for development collaborations or acquisition of the intangible assets related to Sepranolone, and that the conditions for a necessary capital raise for own development of Sepranolone were lacking. Since Asarina no longer conducts any operational activities, and that the Company's shareholders have decided on voluntary liquidation, the Company no longer meets the listing requirements on the Nasdaq First North Growth Market in Stockholm. The last day for trading in the Company's shares on Nasdaq First North Growth Market will be announced through a separate press release when the Company has received confirmation thereof from Nasdaq First North Growth Market.
Until the liquidation date, December 1, 2024, the Company's management and board will continue the work of finding buyers for Asarina's tangible and intangible assets.
For further information, please contact:
Peter Nordkild, CEO
Tel.: +45 25 47 16 46
Email: peter.nordkild@asarinapharma.com
About Asarina Pharma
Asarina Pharma AB (publ) is a Swedish biotechnology company. The company was founded in 2006 and the share has been traded since September 2018 on the Nasdaq First North Growth Market. Asarina Pharma AB (publ) is based in Solna. Asarina Pharma AB (publ) is listed on the Nasdaq First North Growth Market. The company thus follows the regulations that apply to First North. The company's Certified Adviser is Carnegie Investment Bank AB (publ).
For further information see our website: www.asarinapharma.se.
